Acute Decompensated Heart Failure Clinical Trial
— TUFOfficial title:
Primary Mode of Therapy in Acute Decompensated Heart Failure:Comparison Between Usual Care Plus Tolvaptan and Ultrafiltration.
Verified date | February 2015 |
Source | The Christ Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
For patients hospitalized with acute decompensated heart failure,volume removal remains the
primary therapeutic objective. The current standard of care remains loop diuretics.The high
likelihood of readmissions and poor outcomes highlights the need to examine and improve
in-hospital protocols for these patients. Ultrafiltration allows for greater volume removal,
less neurohormonal stimulation and greater sodium removal.However it is associated with
increased costs, line complications, and relative immobility during treatment. Tolvaptan in
addition to diuretic therapy has been shown to improve the amount of volume removed compared
to diuretic alone.
The study proposes to compare the strategy of adding tolvaptan to usual care with
ultrafiltration as primary mode of therapy in acute decompensated HF(ADHF) patients.
Hypothesis: addition of tolvaptan to usual care for hospitalized HF patients will result in:
- greater volume and weight reduction compared with usual care
- similar efficacy outcomes compared with ultrafiltration, with less complications of
therapy
Status | Completed |
Enrollment | 45 |
Est. completion date | December 2015 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - 2 of 3 physical exam findings of volume overload (rales, JVP over 5 cm and edema) - BNP over 300 - no contraindication to ultrafiltration (line insertion, heparin use) Exclusion Criteria: - serum creatinine > 3mg/dL or Na > 145 - inotrope or vasopressor dependency - active infection, including urinary tract - resynchronization therapy or coronary intervention in past 30 days - life expectancy less than 6 months - hypertrophic obstructive cardiomyopathy with peak resting gradient > 20 mmHg - IV contrast or NSAID use in the past 1 week (uNGAL related requirement) |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | The Christ Hospital | Cincinnati | Ohio |
Lead Sponsor | Collaborator |
---|---|
The Christ Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | nursing intensity | day 1,2,3,4,5 | No | |
Other | peripheral vs. central access, number of filters used, complications of heparin use | day 1,2,3,4,5 | No | |
Primary | Net change in weight | day 1,2,3,4,5 | No | |
Secondary | net volume loss | day 1,2,3,4,5 | No | |
Secondary | urinary NGAL | Day 1,2,3,4,5 | No | |
Secondary | dyspnea score | baseline and day 5 | No | |
Secondary | BNP change from admission to discharge | baseline and day 5 | No | |
Secondary | serum creatinine change | Day 1,2,3,4,5 | No | |
Secondary | serum sodium and potassium changes | baseline through day 5 | No | |
Secondary | Quality of Life | day 4 of hospital stay | No | |
Secondary | all cause readmission | 30 day | No | |
Secondary | all cause death | 30 day | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04049045 -
Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure
|
Phase 2 | |
Active, not recruiting |
NCT05100836 -
SURPASS Impella 5.5 Study
|
||
Recruiting |
NCT02898181 -
Low Level Tragus Stimulation in Acute Decompensated Heart Failure
|
N/A | |
Completed |
NCT02823626 -
High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure
|
||
Completed |
NCT02196038 -
A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients
|
N/A | |
Completed |
NCT02248831 -
Evaluation of Cardiopulmonary Diseases by Ultrasound
|
N/A | |
Completed |
NCT00693745 -
Neutrophil Gelatinase-Associated Lipcalin (NGAL) Evaluation Along With B-Type Natriuretic Peptide in Acutely Decompensated HF
|
N/A | |
Not yet recruiting |
NCT04391231 -
HEMolysis in a Percutaneous Axial Flow LVAD, Effects of Pentoxifylline in a Randomized Controlled Trial
|
Phase 4 | |
Recruiting |
NCT05206422 -
DORAYA-HF Early Feasibility Study
|
N/A | |
Recruiting |
NCT01960218 -
Gas Exchange for Predicting Hospital Heart Failure Readmissions
|
N/A | |
Terminated |
NCT00904488 -
Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure
|
Phase 4 | |
Terminated |
NCT02620384 -
Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.
|
Phase 3 | |
Completed |
NCT04318093 -
Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure
|
Phase 2 | |
Recruiting |
NCT06161649 -
Mobile Education System to Improve Disease Knowledge, Self-efficacy and Quality of Life in Patients With Heart Failure
|
N/A | |
Completed |
NCT02289508 -
Role of USCOM in Adult Patients With Heart Failure
|
N/A | |
Terminated |
NCT01457053 -
Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics
|
N/A | |
Completed |
NCT04877652 -
DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics
|
||
Completed |
NCT03505788 -
Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR)
|
Phase 4 | |
Completed |
NCT03146754 -
A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravascular Lung Water Induced by Positional Changes (LUPE)
|
N/A | |
Terminated |
NCT05346653 -
The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure
|
Phase 4 |